Year: 2019

– Robust Hemoglobin Increases Maintained in 18 Patients in the Extension Phase of the Study with Median Treatment Duration of Three Years –– Cumulative Safety Profile (Core Period plus Extension Phase) Continues to Support Long-term Twice Daily Dosing of Mitapivat –– Data from the Natural History Study Demonstrate that PK Deficiency Patients, Regardless of Transfusion Status, Have Higher Rates of Select Comorbidities and Complications –– Company to Host Investor Event and Webcast Today at 8:00 p.m. ET –ORLANDO, Fla., Dec. 09, 2019 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today reported new data from the extension phase of the DRIVE PK Phase 2 study of mitapivat (AG-348) in adults with pyruvate kinase (PK) deficiency at the...

61 patients with diverse EBV-associated diseases, including 26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® (tabelecleucel) EAP studyTab-cel® was generally well-tolerated in all patients with EBV+ PTLD and other EBV-associated diseasesEstimated two-year overall survival rate in tab-cel® responders was 86 and 100 percent for patients with EBV+ PTLD following HCT and SOT, respectively, with median time to response of one monthSimilar outcomes observed in subgroup of 22 patients with EBV+ PTLD who would have likely met eligibility criteria for Atara’s ongoing tab-cel®Phase 3 studiesSOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) — Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer,...

STAMFORD, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that its collaborator, GlaxoSmithKline, presented data evaluating SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat (formerly PF-03084014), alone and in combination with GlaxoSmithKline’s investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC), belantamab mafodotin (formerly GSK2857916), in preclinical cell line models of human multiple myeloma and other lymphomas. The data demonstrated that treatment of BCMA-expressing cancer cell lines with nirogacestat led to significantly increased levels of cell surface expression of BCMA and...

– 2.4 g/dL mean increase in hemoglobin at 24 weeks –– Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis –– Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020 –

AUSTIN, Texas, Dec. 09, 2019 (GLOBE NEWSWIRE) — Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics, today announced the presentations of two posters on its pipeline programs at the American Society of Hematology (ASH) 2019 Annual Meeting, taking place December 7-10, 2019 in Orlando, Florida.   One of these posters includes final results from the Phase 1/1b study of MT-3724, in subjects with relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL).This is a multi-center, open-label, dose-escalation and dose-expansion study of MT-3724, the first CD20 targeted immunotoxin to enter clinical trials.  The Phase 1/1b portion of the study...

Preliminary data showed continuing signs of activity across a broad range of parameters, suggesting possible disease-modifying effects of CPI-0610In the first-line treatment arm, 12 out of 15 (80%) evaluable JAK-inhibitor-naïve patients treated with a CPI-0610 / ruxolitinib combination achieved at least a 35% spleen volume response (SVR35) at 12 weeksClinical activity, including SVR35 responses, TSS50 responses, and conversion from transfusion dependence to transfusion independence, was seen at 24 weeks in patients in the second-line treatment arm who added CPI-0610 to ruxolitinib, suggesting that treatment with CPI-0610 may have durable effectsAn investor event to discuss the MANIFEST update at ASH is scheduled for 12:30 PM EST todayCAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) — Constellation Pharmaceuticals, Inc., a clinical-stage...

ATLANTA, Dec. 09, 2019 (GLOBE NEWSWIRE) —Expansion of UPS Worldwide Express® and UPS Express® Plus delivery to over 3,200 new postal codes across 40 countries including five new countriesUPS Worldwide Express Freight® delivery expands by nearly 8,000 postal codes across 11 countries including four new countriesUPS (NYSE:UPS) today announced an expansion across 40 countries of its UPS Worldwide Express and UPS Express Plus, part of the UPS international suite of shipping services that guarantees time- and day-definite delivery for urgent shipments. UPS express services are now available to businesses across 140 countries and territories, reaching the top 20 countries by GDP with morning delivery. The latest expansion offers morning or midday service for companies looking to improve time to market, speed inventory replenishment and...

NAXS has made a commitment to JAB Consumer Fund – Global Consumer Brands III (the “Fund”).The Fund co-invests with JAB Holding, a privately held group focused on consumer goods & services companies with premium brands. Previous transactions by JAB Holding include Keurig Green Mountain, Krispy Kreme, Espresso House, Dr Pepper and Pret a Manger.The Fund will provide an exposure to recent transactions by JAB Holding, including the recently announced acquisitions of Compassion First Pet Hospitals and National Veterinary Associates.NAXS is an existing investor in JAB’s predecessor fund, JAB Consumer Fund – Global Consumer Brands II.Contact information:Lennart Svantesson, CEOTelephone: +46 73 311 00 11This information was submitted for publication, through the agency of the contact person set out above, at 16:00 CET on December 9, 2019.This...

NAXS har gjort ett investeringsåtagande gentemot JAB Consumer Fund – Global Consumer Fund III (”Fonden”).Fonden saminvesterar med JAB Holding, en privatägd företagsgrupp med fokus på varumärken i premiumsegmentet inom konsumentvaror & tjänster. Tidigare investeringar gjorda av JAB Holding omfattar bl.a. Keurig Green Mountain, Krispy Kreme, Peets Coffee, Espresso House, Dr Pepper och Pret a Manger.NAXS investering i Fonden medför en exponering mot av JAB Holding nyligen offentliggjorda förvärv av Compassion First Pet Hospitals och National Veterinary Associates.NAXS är sedan tidigare investerare i den föregående fonden JAB Consumer Fund – Global Consumer Brands II.KontaktinformationLennart Svantesson, verkställande direktörTelefon: +46 73 311 00 11Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande...

Atlanta, Dec. 09, 2019 (GLOBE NEWSWIRE) — Acuity Brands, Inc. (NYSE: AYI) introduced today the Modulus™ low voltage distributed power and control system providing digital control and network technologies for LED luminaires. The Modulus system provides the same extensive capabilities as the best of Acuity Brands’ control and driver systems, such as flicker-free dimming, networked lighting controls and embedded sensors, emergency battery back-up and tunable white.The Modulus system uses a single unit for powering a luminaire run of up to 32 feet versus requiring a unit every eight feet, which reduces the total cost of ownership. This configuration provides flexible lighting design as it allows for Modulus technology to be embedded in a multitude of new luminaire form factors.“There’s a market need for ever smaller, unobtrusive luminaires...